Ulcerative Timeline to a cure

Authors: Jay Pravda

Abstract

Ulcerative colitis has baffled researchers since the early 20^th^ century. The prevailing explanation attributes the chronic recurring episodes of bloody diarrhea and abdominal pain to some form of immune abnormality, despite the lack of supporting evidence. This highlights the critical need for innovative research directions and methodologies to uncover the cause and develop a cure for this disease. By analyzing existing data from less than a dozen previously published studies, a novel, evidence-based pathogenesis was constructed, implicating colonic epithelial hydrogen peroxide as a causal factor in the development of this disease. This newly identified mechanism informed the creation of a groundbreaking class of therapeutics, known as reducing agents, which have demonstrated remarkable success in resolving colonic inflammation and restoring colonic health in patients with refractory ulcerative colitis. This paper outlines the timeline of these publications and reinterprets the findings within the context of contemporary biomedical science.

Core Tip: Since the mid-20^th^ century, research into the causes of ulcerative colitis has predominantly focused on the immune system and microbiome, overlooking the colonic epithelium’s role in its pathogenesis. This conformation bias has delayed recognition of the causal role played by colonocyte hydrogen peroxide in the pathogenesis of this inflammatory bowel disease. Notably, fewer than a dozen studies since that time have laid the groundwork for this conclusion. This review critically examines these foundational studies through the lens of contemporary biomedical science, tracing their evolution toward the identification of a causal role for colonocyte hydrogen peroxide in the pathogenesis of ulcerative colitis.

INTRODUCTION

Ulcerative colitis (UC) is a major inflammatory bowel disease that leads to chronic episodes of relapsing and remitting bloody diarrhea and rectal bleeding lasting weeks, months or in some cases years. Typically manifesting during the second and third decades of life, the inflammation associated with UC originates within the colonic epithelium, where three distinct cell types converge. Neutrophils, the initial responding immune cells, migrate into the colonic epithelium, interacting with colonic epithelial cells and the microorganisms constituting the microbiome[1].

Research focused on the microbiome and immune system, spanning back to the early 20^th^ century, has failed to clarify why neutrophils the most abundant innate immunocyte suddenly migrate en masse into the colonic epithelium of otherwise healthy young individuals in the prime of life. This has led to a default explanation of ‘immune dysregulation’ (and its various iterations) as a means to impart a sense of conceptual progress towards identifying the cause of this disease[2]. Just what is meant by ‘immune dysregulation’ is not clear. However, for as long as research has been ongoing to uncover the etiology of UC, no pathological organism or pre-existing immune vulnerability has been discovered to account for the development of this condition.

Nevertheless, in the mid-20^th^ century, a third area of research emerged, focused on the colonic epithelium, which revealed an active causal involvement of colonic epithelial cells (colonocytes) in the pathogenesis of UC. By the early 21^st^ century, cumulative experimental and clinical evidence converged into a coherent, evidence-based pathogenesis, substantiating the hypothesis about the pivotal role of the colonic epithelium in the development of this disease. This paper chronicles the significant paradigm shift in the perception of UC etiology, transitioning from a groundbreaking yet unconventional theory of the mid-20^th^ century to its experimental validation over the course of five decades.

Operationally, the investigation into the potential causal agent of UC was refined by excluding the microbiome and immune system, as no evidence supported their involvement in the pathogenesis of disease. This process highlighted the colonic epithelium as the primary participant in the development of UC. Given that neutrophils are the initial responders into the colonic epithelium, attention turned to identifying a small, membrane-permeable, neutrophilic chemotactic factor originating in colonic epithelial cells. Subsequent research identified hydrogen peroxide (H2O2) as a viable candidate since all cells produce H2O2 during the course of cellular metabolism. H2O2 is both membrane permeable and a potent neutrophilic chemotactic agent. Colonocyte H2O2, when secreted into the extracellular space, would attract neutrophils into the colonic epithelium leading to colonic inflammation and UC. This was a biologically sound mechanism that satisfied the known histological data.

In contrast, the prevailing theory of immune dysregulation lacks evidence of immune vulnerability associated with UC. It also fails to offer specific clinical management strategies or curative therapeutic targets. An H2O2-based redox mechanism, however, provides a framework for targeted primary, secondary, and tertiary prevention, as well as potential curative approaches. Examples include mitigating oxidative stress (primary prevention), detecting excess H2O2 via stool analysis or during colonoscopy (secondary prevention), and eliminating excess H2O2 from the colonic lamina propria (tertiary prevention). Restoring normal H2O2 levels in colonic epithelial cells is a potential functional cure for UC.

Subsequent research identified environmental factors linked to UC as oxidative stressors that elevate cellular H2O2 production, facilitating its diffusion from colonocytes. Consistent with this mechanism, the predisposition to UC was attributed to an impaired ability to manage an acute H2O2 (oxidative) load. This understanding led to the development of therapeutic reducing agents aimed at enhancing cellular reductive capacity to address the underlying root cause of excessive H2O2. The lack of casual evidence for abnormalities of the immune system and microbiome coupled with the complete novelty of this H2O2-based mechanism made confirmation bias highly improbable. Notably, fewer than a dozen studies formed the foundational evidence implicating colonic epithelial H2O2 as the etiological agent of this debilitating disease. These pivotal studies are outlined below in chronological order, although their discovery followed a less direct path.

TIMELINE

1948

First report of fatal UC following the self-administration of a H2O2 enema[3]. The report prompts an important Why does H2O2 specifically induce UC rather than other forms of colitis, such as ischemic, collagenous, or lymphocytic colitis? What unique properties of H2O2 lead to UC upon interaction with the colonic mucosa? Crucially, could the unique properties of H2O2 offer insights into the mechanisms underlying the development of UC?

1949

This groundbreaking study offered the first empirical evidence highlighting the critical role of colonic epithelial cells in the pathogenesis of UC[4]. After reviewing nearly 200 colonic biopsies, two pathologists concluded that UC is caused by an unknown chemical secreted by colonic epithelial cells. This was a radical departure from current thinking at the time and still is. The findings implied that colonic epithelial cells release a small membrane-permeable molecule with chemotactic properties for neutrophils-the first responder white blood cells entering the colon and leading to UC development. This study laid the foundational framework for a therapeutically actionable pathogenesis of disease. Unlike all other hypotheses proposed to explain UC, both historically and in subsequent research, this study represented direct empirical evidence establishing a causal role for the colonic epithelium in the pathogenesis of UC. More significantly, it provided a mechanism capable of accounting for all cases of the disease. This marked the first pivotal theoretical breakthrough in advancing our understanding of UC.

It is important to highlight that the authors of this study were pathologists rather than clinical practitioners directly involved in UC patient care. Clinical specialists had previously hypothesized several potential etiologies, including infection, psychogenic factors, allergies, autoimmune conditions, connective tissue abnormalities, cholinergic mechanisms, ischemia, and cytolytic enzymes, though none of these could be definitively established[5]. This underscores the value of approaching longstanding challenges from a fresh perspective. A new viewpoint can foster innovative thinking and generate creative solutions that have the potential to drive breakthroughs otherwise unattainable through conventional derivative approaches.

1951

Two cases of severe ulcerative proctosigmoiditis are documented following the administration of H2O2 enemas[6]. These findings suggest a mechanism beyond a generic chemical injury, as enemas typically reach up to the splenic flexure but the inflammation did not reach that high[7]. Additionally, it raises an important question regarding why the inflammation was limited to the rectum and sigmoid colon, mirroring the presentation of UC observed in many patients. This prompts consideration of whether the colon interacts with H2O2 differently from other chemicals and/or or whether a gradient of protection against H2O2’s effects exists, increasing in more proximal regions of the colon. These observations emphasize the necessity of conducting a study to assess whether human UC can be reproduced in an animal model. This was addressed in the following study.

1960

Researchers successfully reproduce what they describe as acute and chronic UC by the administration of H2O2 enemas in rats[3]. This represented the first chemically-induced animal model replicating features found in the micro and macroscopic presentation of human UC. This raised further questions regarding how H2O2 enemas trigger UC in animals and humans. Additionally, it sparked inquiries into whether this phenomenon has a connection to naturally occurring human UC. Interest in H2O2 was further heightened by a review describing the histology of 14 chemicals causing colitis in which only H2O2 is described as being similar to UC[8]. This drew attention to H2O2, especially in view of the next study.

1970

Scientists discover that living cells generate H2O2[9]. This study marked the first biochemical evidence suggesting that H2O2 produced by colonic epithelial cells is the previously unidentified chemical secreted by colonic epithelial cells leading to the development of UC. Given that H2O2 is a well-known oxidizing agent, the findings highlighted the possibility that oxidative stress arising from excessive colonic epithelial H2O2 production plays a role in the pathogenesis of UC. This study served to focus inquiry on the biophysical and biochemical properties of H2O2, its cellular origins, and the ways in which environmental factors associated with UC may elevate intracellular H2O2 levels within colonic epithelial cells.

1979

An essential advancement in understanding emerged with the discovery that H2O2 is highly permeable through cell membranes[10]. Specific membrane aquaporin channels, known as peroxiporins, were subsequently identified as facilitators of H2O2 transmembrane permeability[11]. This finding established a mechanism by which H2O2 could exit colonic epithelial cells and engage with the innate immune system-an indispensable process if H2O2 is to play a role in the pathogenesis of UC. Peroxiporins are also found on mitochondrial membranes[12]. This allows diffusion of mitochondrial H2O2 throughout the cell to serve a messenger function but also provided a means for H2O2 to flood the cell during times of excess H2O2 production.

1987

5-aminosalicylic acid (5-ASA), the mainstay for the treatment of UC, is determined to be a reducing agent (antioxidant or radical scavenger)[13]. 5-ASA reacts efficiently with H2O2, during which 5-ASA undergoes oxidation to form the corresponding quinone-imine while simultaneously reducing H2O2 to water, as demonstrated in the following reaction (Figure 1).

The reaction proceeds spontaneously; however, its rate can be enhanced by peroxidases present in the inflammatory environment, such as neutrophilic myeloperoxidase, or by bacterial peroxidases located in the colonic lumen[14-16]. Significantly, 5-ASA exhibits therapeutic specificity for the inflammation associated with UC and does not function as a general anti-inflammatory agent[17]. Later studies demonstrated elevated colonic H2O2 in the uninvolved colonic epithelium in UC but not in Crohn’s disease or healthy controls (detailed below). These observations lend further support to a causal role for H2O2 in the pathogenesis of UC.

5-ASA was first synthesized as the prodrug sulfasalazine in 1939 by combining the antibiotic sulfapyridine with salicylic acid[18]. In this compound, sulfapyridine is linked to carbon 5 of salicylic acid’s aromatic ring via an azo bond (Figure 2).

After ingestion, 5-ASA is released from sulfasalazine (along with sulfapyridine) when acted upon by bacterial azo reductase in the colon (Figure 3). A total of 4 electrons are donated by azo reductase to reduce the azo bond[19]. Two electrons are added to generate the reduced form of 5-ASA while two remain with sulfapyridine. The reduction of the azo bond introduces an amino group at the aromatic-ring’s 5^th^ carbon of salicylic acid, a compound devoid of therapeutic activity in UC or H2O2 reducing capacity. This process transforms salicylic acid into 5-ASA, a H2O2 reducing agent with targeted efficacy in treating UC. The two electrons added by bacterial azo reductase to create 5-ASA facilitates its function as a reducing agent. This transformation suggests a key therapeutic role for the newly acquired reductive capacity of 5-ASA.

This supports a mechanism whereby 5-ASA induces remission by acting as a topical reductive sink for neutrophil generated H2O2. This eliminates the H2O2-dependent chemotactic signal that attracts additional neutrophils into the colonic lamina propria. 5-ASA can maintain remission by continuing to serve as a reductive sink for H2O2 diffusing from colonic epithelial cells, thereby preventing relapse. The capacity of 5-ASA to act as a reducing agent and interact with H2O2 further reinforces the evidence supporting H2O2’s causal role in the pathogenesis of UC.

1994

This study identified abnormal cellular metabolism in colonic biopsies from individuals with UC in remission. Specifically, it demonstrated the inhibition of beta-oxidation of n-butyrate, a short-chain fatty acid that serves as a primary energy source for colonic epithelial cells[20]. This finding holds substantial significance as beta-oxidation takes place in the mitochondria, the primary site of cellular H2O2 generation. Notably, the inhibition of beta-oxidation was observed weeks prior to relapse supporting the notion of a colonic epithelial abnormality preceding disease recurrence[21]. It further suggests the possibility that the inhibition of beta-oxidation might result from an initial accumulation of H2O2, which subsequently exits the cell, initiating the development of UC. These findings provide biochemical evidence highlighting a critical role of the colonic epithelium in the pathogenesis of UC.

H2O2 was subsequently demonstrated to inhibit beta-oxidation (discussed further below). This progression suggested that the initial accumulation of H2O2 within mitochondria resulted in the inhibition of beta-oxidation. This was followed by relapse weeks later as mitochondrial H2O2 diffused into the cytoplasm and, ultimately, into the extracellular space.

1996

H2O2 is shown to be highly chemotactic for neutrophils[22]. This was another critical piece of the puzzle. This phenomenon explains why H2O2 introduced into the colons of mice and humans (inadvertently during colonoscopy) can lead to the onset of UC. H2O2 is one of the few molecules that are capable of attracting neutrophils, which are the first responding cells in UC. Given that H2O2 is bio-membrane permeable, it indicated that excess H2O2, when present in the colonocyte**,** could easily diffuse through the colonocyte cell membrane into the lamina propria, where blood vessels reside. Once in the lamina propria, H2O2 would initiate the directed migration of neutrophils from the blood vessels, via diapedesis, into the colonic epithelium and subsequently the development of UC. The precise mechanism by which H2O2 attracts neutrophils was elucidated in 2021[23].

Up until now we know that H2O2 is produced intracellularly and is a biomembrane permeable neutrophilic chemotactic agent that is capable of causing UC when introduced into the colon. This observation suggested that UC may originate from the primary accumulation of H2O2 within colonic epithelial cells. The remaining critical question Can colonic epithelial cells generate sufficient levels of H2O2 to initiate UC? The next study provided the missing evidence and addressed this pivotal gap in knowledge.

2001

Glutathione peroxidase knockout mice, which lack the ability to neutralize H2O2, develop colitis that closely resembles human UC[24]. This finding represents a pivotal piece of evidence, demonstrating that colonic epithelial cells are capable of producing sufficient H2O2 to induce UC. This study further substantiated the causal role of the colonic epithelium in the pathogenesis of UC. It also confirmed prior hypotheses that an accumulation of excess H2O2 within colonic epithelial cells is the underlying cause of this disease.

2006

This study demonstrated that the distal large intestine (rectum) has the lowest reductive capacity of the entire large intestine[25]. This observation provides a biologically sound explanation for the long-standing question of why UC originates in the rectum and progresses proximally. The reduced reductive capacity results in the rectum becoming the initial site for H2O2 accumulation. As H2O2 diffuses into the colonic epithelial extracellular space, it attracts neutrophils, leading to the development of UC. The observed decline in reductive (antioxidant) capacity from the proximal to distal colon aligns seamlessly with H2O2 playing a causal role in the pathogenesis of UC. To date, no alternative explanation has adequately addressed why UC begins in the rectum and advances proximally. This finding adds to the cumulative evidence supporting an etiological role for H2O2 in UC pathogenesis. This observation contributes to the growing body of evidence that supports H2O2 as a causal factor in the pathogenesis of UC.

2007

This study was the first to report significantly elevated levels of H2O2 production in colonic biopsies from individuals with UC in remission, compared to those with Crohn’s disease or healthy controls[26]. This discovery provides compelling evidence supporting the role of colonic epithelial H2O2 as the etiological agent in the development of UC. Moreover, the detection of elevated H2O2 levels in colonic epithelial cells prior to the onset of colitis fulfills the absolute criterion of temporality required to establish a cause-and-effect relationship between H2O2 (the cause), which must be present before UC (the effect).

These results also resolved the long-standing question of why the inhibition of colonic epithelial cell beta-oxidation is followed, after several weeks, by disease relapse[21]. As mitochondrial H2O2 levels continue to rise, it first inhibits mitochondrial thiolase leading to impaired beta-oxidation after which H2O2 exits the mitochondrion and enters the cytoplasm. Subsequently, it diffuses through the cell membrane into the colonic epithelial extracellular space, where it attracts neutrophils to the colon, ultimately leading to the development of UC. The entire interval can span several weeks (discussed below).

This approach highlights the critical importance of analyzing pre-existing experimental data to develop a biologically coherent model of pathogenesis, subsequently validated through laboratory experimentation. The practical result is the formulation of an innovative therapeutic strategy for the treatment of UC. This novel intervention targets the colonic epithelium by supplying the deficient reducing equivalents necessary to neutralize excess H2O2, thereby re-establishing and maintaining redox homeostasis.

By eliminating the H2O2-induced immunologic chemotactic signal that attracts neutrophils into the colonic epithelium, this approach resolves colonic inflammation and leads to the complete resolution of UC[27]. In other words, achieving colonocyte redox homeostasis prevents the diffusion of H2O2 into the extracellular environment, halting neutrophilic infiltration and recurrent episodes of UC. This is the same mechanism used naturally by the colonocyte to prevent extracellular diffusion of H2O2. Ultimately, this outcome represents a functional cure.

At this point, we have come full circle, showcasing the classic bench-to-bedside application of experimental evidence to establish a causal role for colonic epithelial H2O2 in the pathogenesis of UC. This breakthrough has led to an effective new treatment approach and holds promise for a potential cure for this chronic, debilitating disease.

DISCUSSION

H2O2 generation

All cells generate H2O2 as consequence of cellular metabolism. The production of H2O2 is not static and is influenced by the fluctuating nature of metabolic activity in the cell at any given time. To maintain redox homeostasis and prevent the buildup of H2O2 cells must adjust their reductive (antioxidant) capacity in response to these fluctuations. This involves modulating the synthesis of reducing equivalents, such as glutathione and thioredoxin, to prevent the harmful accumulation of H2O2 within the cell. Such adaptive mechanisms enable cells to enhance their metabolic activity in response to external stimuli without adverse effects from excess intracellular H2O2. However, if H2O2 production surpasses the reductive capacity of the colonocyte, intracellular H2O2 can accumulate and diffuse through the cell membrane into the extracellular microenvironment. This diffusion triggers the recruitment of intravascular neutrophils to the colonic epithelium, ultimately leading to the development of UC (Figure 4)[28-30].

Loss of redox homeostasis

Thus, external (to the cell) stimuli are transduced to the cell interior as a change in metabolic activity, which can translate into higher H2O2 levels. Various external factors can enhance H2O2 production through alterations in cellular metabolism. A good example is the metabolism of soluble fiber in the colon to form n-butyrate, a short chain fatty acid that provides most of the energy used by the colonic epithelial cell. Normally, ingested soluble fiber is fermented by colonic bacteria to generate n-butyrate and other short chain fatty acids. N-butyrate is absorbed by colonic epithelial cells and provides 70%-80% of the energy used by colonic epithelial cells[31]. Lumenal soluble fiber is the beginning of a sequential bioenergetic pathway that includes colonic bacteria, butyrate, beta-oxidation and acetyl CoA. A deficiency of any one of these elements can usher in metabolic changes, leading to a loss of redox homeostasis and the accumulation of cellular H2O2. This can raise the risk of relapse or developing UC as illustrated in Figure 5A[32-34].

Other cellular sources become significant generators of H2O2 when exposed to specific oxidative stressors. Thus, mitochondria (smoking cessation), high fat diet (peroxisomes), drug metabolism (smooth endoplasmic reticulum), monoamine oxidase (stress) all known risk factors for UC can increase cellular H2O2 (Figure 5B)[35-38]. These processes establish a clear link between environmental factors that drive H2O2 production and the development of UC. This implies that H2O2 serves as the final common pathway through which environmental factors contribute to the pathogenesis of UC.

Oxidative stress

By definition, external stimuli that generate H2O2 are known as oxidative stressors. Exposure to these environmental oxidative stressors significantly increases the risk of developing or worsening UC. H2O2 is a potent cell membrane permeable neutrophilic chemotactic agent whose intracellular production is increased by exposure to environmental oxidative stressors. These characteristics establish H2O2 as both a necessary and sufficient causal factor in UC. Given that the final common pathway for all oxidative stressors in UC is H2O2, exposure to multiple contemporaneous sources of oxidative stress is cumulative over the short term. Cumulative exposure to oxidative stress can overwhelm cellular reductive capacity leading to UC.

New classification of UC

From an immunological perspective, H2O2 is an immune signaling agent that is inappropriately secreted by the colonic epithelium. However, the colonic epithelium is also capable of secreting other neutrophilic chemotactic agents that contribute to a histological presentation consistent with UC. This is exemplified by a documented case of UC arising in the context of disseminated candidiasis, which was successfully treated with anakinra, an interleukin (IL)-1 receptor antagonist[39]. In this case, IL-1 produced by activated macrophages induced colonic epithelial cells to secrete IL-8, which is a strong neutrophil chemotactic agent. Antagonism of colonic epithelial cell IL-1 receptors with anakinra prevented IL-8 secretion thereby resolving the colitis. These findings suggest that UC may be classified based on the specific chemotactic agent driving its pathogenesis, with H2O2 being the most prevalent. This further implies that the use of reducing agents to neutralize H2O2 could serve both diagnostic and therapeutic purposes. A positive therapeutic response would confirm a causal role for H2O2, whereas a lack of response would indicate involvement of an alternative chemotactic agent. Partial responses might signify a combined presence of H2O2 and other oxidative stressors, such as infection.

Recognizing environmental oxidative stressors entails probing the lived experience of patients with UC. Multiple jobs, school, work, sleep deprivation, dietary history, medication use, recent relocation, smoking cessation, lifestyle, etc., can provide clues to identify the source of oxidative stress that can be targeted for mitigation. It can also provide clues to the cellular source of excess H2O2 as indicated above.

H2O2 explains the entire pathogenesis of UC

The evidence supporting a causal role for colonic epithelial cell H2O2 in the pathogenesis of UC is compelling. Patients with refractory UC have achieved histologic remission through the use of reducing agents, which neutralize excess colonic H2O2 by providing the reducing equivalents required by the colonic epithelium. This is supported by cessation of rectal bleeding within 1-2 weeks after initiation of treatment in addition to colonic biopsy results showing histologic remission in a case series of 36 patients with refractory UC[40]. Unsolicited feedback was received from one patient with a 30 + year history of refractory UC who was treated in 2007. His colonoscopy and biopsy performed 12 years later in 2019 was completely normal. The patient continues asymptomatic as of the date of this publication[41].

The use of reducing agents such as sodium thiosulfate (STS) and R-dihydrolipoic acid (RDLA) to induce and maintain remission, respectively, in UC is based on the evidence indicating that H2O2 plays a causal role in the pathogenesis (development) and pathophysiology (mucosal inflammation) of this inflammatory bowel disease. STS is an orally administered, water soluble extracellular reducing agent that is thought to neutralize H2O2 in the colonic lamina propria. This action abrogates the H2O2-induced chemotactic signal attracting neutrophils into the colonic epithelium, which induces remission. RDLA is a lipid soluble intracellular reducing agent that can normalize colonic epithelial cell H2O2, which maintains remission indefinitely as long as H2O2 does not exist the cell. Both have favorable safety profiles[42,27].

Evidence indicates that UC can be cured

Based on the available evidence, treatment with reducing agents represents a cure for UC in the same way that vitamin C is a cure for scurvy. This implies that relapse cannot occur as long as colonic redox homeostasis is maintained, which prevents the extracellular diffusion of colonic epithelial cell H2O2, thereby precluding the recruitment of neutrophils into the colonic epithelium. In contrast, nearly 25% of patients with UC do not respond to biologics and almost 60% of patients eventually lose their response[43]. Additionally, biologics (an immunosuppressive agent) neither offer a cure for UC nor significantly reduce the risk of surgical intervention in cases of moderate to severely active UC[44]. Furthermore, studies report that 66%-88.5% of patients with UC receiving Janus kinase (JAK) inhibitors (another immunosuppressive agent) fail to achieve clinical remission with 34%-52% maintaining clinical remission at one year[45]. Notably, even induction rates for emerging therapeutic agents remain stagnated, at approximately 20%-30% in clinical trials[46].

Tweaking a study to orchestrate significance helps profits, not patients

Numerous strategies have been proposed to enhance the response rates to immunosuppressive agents[46], (1) Excluding refractory patients from clinical trials; (2) Administrating multiple immunosuppressive agents to individual patients; (3) Reducing placebo response rates by employing central reading to achieve statistical significance; (4) Replacing human central reading with automated systems; (5) Developing new scoring systems that are better suited to the limitations of immunosuppressive agents; (6) Implementing stricter exclusion criteria to identify trial participants who are using other medications (e.g., steroids); (7) Establishing new endpoints to evaluate therapeutic response; (8) Employing innovative clinical trial designs; and (9) Introducing standardized biopsy sampling procedures.

These methodological modifications are designed to increase statistical significance of clinical trials in order to secure regulatory approval by compensating for the inherent limitations of immunosuppressive agents, which do not address the underlying cause of UC. While such optimizations to trial design may succeed in gaining approval for additional immunosuppressive therapies, allowing pharmaceutical companies to claim their share of the insurance market, they do nothing to genuinely benefit patients with UC and instead contribute to escalating healthcare costs. An alternative and potentially transformative solution lies in addressing confirmation bias, which perpetuates an exclusive focus on immune dysregulation and ineffective immunosuppressive therapies.

Dependence isn’t accidental

Reflecting on the patient’s journey with a chronic disease such as UC, the cycle of ethical concern revolves around the interplay between learned helplessness and the erosion of personal agency. When individuals are led to believe their condition is incurable, a sense of futility takes hold, fostering dependence and diminishing autonomy. This gives rise to a learned helplessness, reinforced by reliance on long-term, expensive and potentially harmful immunosuppressive medications, creating a feedback loop. The prolonged dependence perpetuates the feelings of helplessness, discouraging individuals from exploring alternative solutions or taking control of their own health. Confined to a system that offers no cure, individuals normalize their illness as a coping mechanism, unaware that they are both patients and victims of the very system from which they seek help. Breaking this cycle necessitates not only empowering individuals to reclaim agency but also challenging established narratives about disease pathogenesis and management.

Research diversity is essential for finding cures

A critical element in disrupting this cycle is fostering research diversity. By encouraging exploration of innovative approaches to disease pathogenesis, we can open doors to new understandings and perspectives that may contradict the prevailing narratives of incurability. Diverse research efforts allow for the examination of novel biological, environmental, and social factors that could reshape our understanding of how diseases develop and progress. Research diversity in inflammatory bowel disease is essential for uncovering the root causes of disease, enabling targeted solutions that address these causes directly rather than relying on symptom management with immunosuppressive agents. This diversity is vital in paving the way for groundbreaking discoveries that challenge entrenched medical dogmas and offer new solutions that restore the public trust in medical research, which is at an all-time low[47].

CONCLUSION

The evidence indicates that UC is a metabolic disease characterized by impaired colonic redox homeostasis leading to excess H2O2, a condition that cannot be effectively treated or cured with immunosuppressive agents. There are approximately 1.9 million individuals living with UC in the United States according to the NHANES 2009-2010 United States inflammatory bowel disease diagnosed prevalence[48]. The continued long-term reliance on immunosuppressive therapies has resulted in a generation of predominantly young individuals with chronic UC who face significant life-long challenges, including an uncertain future, financial insecurity, and persistent emotional distress. These issues are compounded by the narrow focus on developing new and largely ineffective, immunosuppressing drugs. This approach not only jeopardizes the well-being of many young lives but also places an unsustainable financial strain on the healthcare system. The cost of these immunosuppressive agents is reported to range between 50000 Dollars and 75000 Dollars per patient annually in 2021[49]. This represents a lifetime total cost for the prevalent 2016 UC population in the United States of 377 billion Dollars, or 508 billion Dollars when adjusted for inflation in 2025[50]. And that’s just one disease. If the United States government wants to save its healthcare system and preserve sustainability for future generations, it is imperative for United States policymakers to mandate that therapeutic approaches are grounded in an evidence-based understanding of pathogenesis, starting with a thorough evaluation of the current treatment strategies for UC.

The treatment of UC with immunosuppressive therapies including biologics, JAK inhibitors, and small molecules, etc. has reached a therapeutic plateau[51,52]. These interventions are fundamentally limited in their effectiveness, as none address the underlying etiology of UC. Consequently, the therapeutic ceiling can never be overcome, as the efficacy of one immunosuppressive agent is just about as good or bad as the other[53]. As a result, the management of UC has devolved into an unpredictable trial-and-error process-essentially a speculative attempt to determine which, and how many, of the 16 currently approved immunosuppressive drugs a patient can tolerate[54]. This often continues until physicians resort to recommending a total colectomy. These practices amount to unconsented post-marketing human experimentation under the guise of medical care. This is the future for the approximately 30% of the 1.9 million individuals in the United States diagnosed with UC including nearly 600000 children, adolescents, and young adults who are projected to become refractory to all immunosuppressive therapies, ultimately requiring surgical removal of their entire large intestine[55-58].

From 2000 to 2021, nearly 7400 individuals with UC succumbed to their disease, including 440 deaths in 2021 alone[59]. This was accompanied by an increase in the UC mortality rate and the number of annual deaths attributable to UC. Despite the availability of “advanced therapy” immunosuppressive agents (biologics, Janus kinase inhibitors, etc.), mortality rates have shown an upward trend. These therapies do not target the underlying cause of UC and are not curative. This is reflected in the progressive nature of this disease, which often results in severe outcomes, including surgery or death, for many patients. Unfortunately, there is no indication that this ominous trend will improve as long as highly profitable immunosuppressive agents are prioritized as long-term treatments, to the exclusion of innovative therapeutic approaches and alternative perspectives regarding disease pathogenesis. This dire prognosis, coupled with documented reports of undisclosed harms to patients with UC participating in induction and maintenance clinical trials[60,61], underscores profound ethical concerns within the continuum of UC drug approval and patient care. Such practices are not only exploitative but raise serious ethical concerns regarding how these immunosuppressive agents have been able to dominate the entire global therapeutic landscape of inflammatory bowel disease to the exclusion of new ideas or innovative therapies that might lead to a cure and save many lives.

Given the lack of a guiding pathogenesis and the dominance of highly lucrative (but largely ineffective) immunosuppressive drugs, a collective descent into a normalization of deviance within this field appears to have been inevitable. This issue is further exacerbated by the overconfidence on internal expertise, fostering an insular environment perpetuated by uniformity of thought and limited external perspectives, ultimately resulting in a culture deeply resistant to change. The factors contributing to the ethical drift within the field of inflammatory bowel disease are beyond the scope of this review. Nevertheless, they warrant thorough investigation to identify the underlying causes of this decline, so they can be replaced with a research environment that prioritizes and incentivizes creativity and innovation in pathogenesis and therapeutics, thereby maximizing the potential for discovering cures. The optimal achievement of immunosuppressive therapy, including biologics and Jak inhibitors (“advanced therapy”), has been the transformation of UC from a highly fatal disease in the early 20^th^ century to its current status as a progressive condition[62,63]. It is now crucial to move forward and embrace emerging evidence that holds the potential to advance toward a cure.

The pioneering gastroenterologist Sydney Truelove[64] (1913-2002) asserted “The ideal way to treat any disease is based on a thorough knowledge of the aetiology so that the root causes can be attacked directly”. We have the opportunity to apply this principle to UC and potentially achieve a cure. However, without a unified and dedicated effort from leaders in the field to rigorously evaluate the existing evidence, the prospects of alleviating the lifelong suffering and avoiding disfiguring surgeries and heightened risk of death for the millions afflicted by this disease remain unattainable. This was true for peptic ulcer in the past and continues to be relevant for inflammatory bowel disease today.